| Nov 19 |
Preclinical Data Demonstrates Anti-Siglec-15 Treatment Enhanced Generation of Quality Bone with Better Mechanical Properties in Mice with Moderate-to-Severe Osteogenesis Imperfecta
|
| Nov 8 |
NextCure GAAP EPS of -$0.41
|
| Nov 7 |
NextCure Provides Business Update and Reports Third Quarter 2024 Financial Results
|
| Nov 5 |
NextCure Reports Preclinical Data for LNCB74 and Additional Clinical Biomarker Data for NC410 Combo at Society for Immunotherapy of Cancer Annual Meeting
|
| Oct 4 |
NextCure to Give Two Presentations at Society for Immunotherapy of Cancer Annual Meeting
|
| Sep 16 |
NextCure Presented Results of the Phase 1b Study of NC410 in Combination with Pembrolizumab at ESMO 2024
|
| Sep 3 |
Is NextCure (NASDAQ:NXTC) In A Good Position To Deliver On Growth Plans?
|
| Aug 2 |
NextCure GAAP EPS of -$0.55 misses by $0.17
|
| Aug 1 |
NextCure Provides Business Update and Reports Second Quarter 2024 Financial Results
|
| Jun 20 |
NextCure to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference
|
